Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.31 |
| ▸ | ABL2 | P42684 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19152664 | 0.75 | HTT (0.45) | TGFBR1CYP3A4CYP2C8HTTPTK2 | |
| SCHEMBL3466097 | 0.75 | HTT (0.41) | NOS1TGFBR1DAOCYP3A4CYP2C8 | |
| SCHEMBL2596969 | 0.75 | NCF1 (0.41) | TGFBR1CYP3A4CYP2C8HTTPTK2 | |
| SCHEMBL2598373 | 0.75 | MAPKAPK2 (0.38) | NOS1TGFBR1CYP3A4CYP2C8HTT | |
| SCHEMBL29514304 | 0.75 | NOS1 (0.47) | NOS1TGFBR1DAOCYP3A4CYP2C8 | |
| SCHEMBL2598398 | 0.75 | NOS1 (0.47) | NOS1TGFBR1DAOCYP3A4CYP2C8 | |
| SCHEMBL9069902 | 0.74 | NOS1 (0.47) | NOS1TGFBR1DAOCYP3A4HTT | |
| SCHEMBL14912053 | 0.73 | AURKA (0.41) | TGFBR1DAOPRKCIMAPK14POLB | |
| SCHEMBL18237978 | 0.71 | HTT (0.37) | TGFBR1CYP3A4CYP2C8HTTPTK2 | |
| SCHEMBL20874628 | 0.71 | KDM4E (0.46) | TGFBR1HTTPTK2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522598-B2 | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as HDAC6 inhibitors | ORYZON GENOMICS SA (ES) | 2026-01-13 | — | — | US | disclosed |
| CN-120058798-A | Bicyclic TEAD inhibitors | 武汉人福创新药物研发中心有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120004864-A | Bicyclic compounds, compositions comprising the same and uses thereof | 贝达药业股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-114206868-B | 3- (2- (Heteroaryl) -pyridin-4-yl) -5- (trifluoromethyl) -1,2, 4-oxadiazole derivatives as HDAC6 inhibitors | 奥莱松基因组股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240360157-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2024-10-31 | — | — | US | disclosed |
| US-12110276-B2 | Pyrazolo compounds and methods of use thereof | GENENTECH, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4436957-A1 | THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118302411-A | Therapeutic indazole compounds and methods of use thereof for the treatment of cancer | 基因泰克公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240209005-A1 | BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2024-06-27 | — | — | US | disclosed |
| EP-1802621-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB Pharmco Puerto Rico Inc. (PR) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044821-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB PHARMCO PUERTO RICO INC. (PR) | 2006-04-27 | — | — | WO | disclosed |
| EP-0152910-B1 | PYRAZOLOPYRIDINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1989-07-12 | — | — | EP | disclosed |
| EP-0119774-B1 | ANTI-INFLAMMATORY PYRAZOLO PYRIDINES | BEECHAM GROUP PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| US-4670432-A | Pyrazolopyridine derivatives useful in treating inflammation and allergic conditions | BEECHAM GROUP P.L.C. (GB) | 1987-06-02 | — | — | US | disclosed |
| US-4576952-A | Pyrazolopyridine derivatives and their use as anti-inflammatory and/or anti-allergic agents | BEECHAM GROUP P.L.C. (GB) | 1986-03-18 | — | — | US | disclosed |
| US-4559348-A | SKIN DISORDERS | BEECHAM GROUP, P.L.C. (GB) | 1985-12-17 | — | — | US | disclosed |
| EP-0152910-A2 | pyrazolopyridine derivatives | BEECHAM GROUP PLC (GB) | 1985-08-28 | — | — | EP | disclosed |
| EP-0151962-A2 | Pyrazolopyridine derivatives | BEECHAM GROUP PLC (GB) | 1985-08-21 | — | — | EP | disclosed |
| EP-0119774-A1 | Anti-inflammatory pyrazolo pyridines | BEECHAM GROUP PLC (GB) | 1984-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | NOS1 4130/4885TGFBR1 4882/4885DAO 3717/4885 |
| US-20240209005-A1 | BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, ENTPD5 | NOS1 1165/4885TGFBR1 3990/4885DAO 2139/4885 |
| US-12110276-B2 | Pyrazolo compounds and methods of use thereof | THPO, KLK3, TP53 | NOS1 2879/4885TGFBR1 4873/4885DAO 1817/4885 |
| US-20240360157-A1 | TYK2 INHIBITORS | TYK2, JAK2, ABL1 | NOS1 4540/4885TGFBR1 1048/4885DAO 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.